Japan's Oncolys kicks off cancer trial; Endo trades $130M for an Aspen portfolio;

@FierceBiotech: ICYMI Friday: EuroBiotech Report: $ABBV orders $30M of Galapagos' IPO, Indivior aces schizophrenia trial, $GILD inks Danish deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, $GSK. Hyping a tiny, discovery-stage biotech as a quest for an HIV cure smells of desperation. News | Follow @JohnCFierce

> Japan's Oncolys BioPharma kicked off a Phase I trial of a cancer drug licensed from Astellas Pharma, targeting U.S. patients with solid tumors. More

> Endo ($ENDP) paid $130 million for a stable of drugs from South Africa's Aspen Holdings, expanding its portfolio of proprietary and generic treatments. News

> The FDA approved Bayer's antibiotic moxifloxacin to treat plague. Item

Medical Device News

@FierceMedDev: ICYMI: Philips CEO outlines HealthTech vision as shareholders vote to separate lighting biz. Story | Follow @FierceMedDev

@VarunSaxena2: Concordia running trials to expand use of its laser-activated cancer-fighting drug. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown. ICYMI from FiercePharma | Follow @EmilyWFierce

> Bayer responds to article critical of its Essure birth control device under FDA investigation. More

> In a move toward an artificial pancreas, Debiotech gains option for Bayer's iSense CGM. Story

> FDA approves Nevro device that eliminates side effect of spinal stimulation. Article

Pharma News

@FiercePharma: Millions more in funding allocated to battle worst avian flu outbreak in U.S. history. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: Big news! FiercePharmaMarketing will now publish every Monday and Wednesday. More | Follow @CarlyHFierce

> HHS: Actavis could cost the government $6B with Namenda hard switch. Story

> Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys. Report

Animal Health News

> Millions more in funding allocated to battle worst avian influenza outbreak in U.S. history. Report

> Trupanion reports Q1 loss as marketing spend kicks into high gear. Item

> Mars Petcare forms new alliance to expand use of DNA testing in vet hospitals. More

> Aratana tops estimates as Q1 loss narrows. Article

> Zoetis CEO on cost-cutting push: 'We will be much more focused.' Story

Biotech IT News

> SFW Capital Partners closes $345M analytical tools fund. News

> Pfizer, 23andMe start building 5,000-person lupus database. More

> Agilent bolsters presence in clinical lab software sector with Cartagenia buyout. Report

> Medidata links its cloud platform to Apple's ResearchKit. Story

> Buzz: Apple plans to add 23andMe-style spit kits to ResearchKit studies. Article

Pharma Marketing News

> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More

> Secret doctor letter shows Amarin's true 'free speech' leanings. Article

> That Namenda hard switch Actavis wants? It could cost HHS $6B. Item

> Back-to-'Biogen' shift signals wider industry branding trend. News

> Is there a place for pharma in the emerging EHR market? More

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.